What is SUTILAINS used for?

SUTILAINS is indicated for Debridement of wound of skin.

What development phase is SUTILAINS in?

SUTILAINS is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

SUTILAINS

FDA-approved approved Quality 17/100

SUTILAINS is a marketed drug primarily indicated for the debridement of skin wounds, with a key composition patent set to expire in 2028. Its exact mechanism of action remains undisclosed, which may provide a competitive edge by creating a barrier to entry for potential generics. The primary risk lies in the patent expiry in 2028, which could lead to increased competition and potential revenue erosion.

At a glance

Generic name	SUTILAINS
Drug class	Unknown
Target	Unknown
Therapeutic area	Dermatology
Phase	FDA-approved
First approval	1969

Approved indications

Debridement of wound of skin

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SUTILAINS CI brief — competitive landscape report
SUTILAINS updates RSS · CI watch RSS